Angiosarcoma is a rare, malignant sarcoma showing differentiation toward endothelial cells, the cells that line blood vessels and lymphatic vessels. It can develop almost anywhere in the body, but recognized presentations include tumors of the skin, particularly the scalp and face, as well as the breast, deep soft tissues, liver, and heart. Angiosarcoma often infiltrates surrounding tissue and can spread to distant organs. Its appearance, clinical course, and treatment vary substantially according to its location and extent.
Classification and distribution
Angiosarcoma is a type of cancer classified by its vascular differentiation rather than simply by the organ in which it occurs. An angiosarcoma arising in the breast, for example, is biologically distinct from the more common forms of breast cancer, which originate in epithelial tissue.
Major clinical settings include:
- Cutaneous angiosarcoma: most characteristically affects the scalp and face of older adults, although other skin sites can be involved.
- Primary breast angiosarcoma: arises within breast tissue without a preceding radiation-associated setting.
- Radiation-associated angiosarcoma: develops in a previously irradiated region, including the skin and soft tissues of the breast or chest wall.
- Lymphedema-associated angiosarcoma: arises in tissue affected by longstanding lymphedema. This association is traditionally called Stewart–Treves syndrome.
- Deep soft-tissue and visceral angiosarcoma: involves sites such as skeletal muscle, liver, heart, spleen, or bone.
These categories describe clinical contexts rather than wholly separate diseases. Most cases occur in adults, although younger people can also be affected.
Causes and risk factors
For many patients, no specific cause is identified. Established associations include previous radiation therapy and chronic lymphedema. Radiation-associated tumors generally develop after a latency of years. Lymphedema-associated disease can occur after cancer treatment or in other forms of longstanding lymphatic obstruction.
Hepatic angiosarcoma has recognized associations with occupational vinyl chloride exposure, arsenic exposure, and the historical radiographic contrast agent Thorotrast. These exposures do not explain most angiosarcomas at other sites.
Angiosarcoma is not a single genetically uniform tumor. Different clinical subsets can have different molecular changes. Amplification of the MYC gene is particularly associated with radiation- and lymphedema-associated tumors, although it is not present in every such case and is not completely restricted to them.
Clinical features
Symptoms depend strongly on the site.
Cutaneous angiosarcoma may initially resemble a bruise, a reddish-purple patch, or an area of swelling. It may become nodular, bleed, or ulcerate. Some tumors extend diffusely through the skin, with boundaries that are difficult to recognize clinically. Their initially inconspicuous appearance can delay recognition.
Breast angiosarcoma may present as an enlarging mass, swelling, or skin discoloration. Radiation-associated breast angiosarcoma frequently involves the skin of the treated area rather than presenting solely as a deep breast mass.
Deep tumors may produce a mass, pain, or symptoms caused by compression of nearby structures. Visceral disease can cause organ-specific symptoms or internal bleeding. Cardiac tumors may interfere with blood flow or cause fluid accumulation around the heart; hepatic tumors may produce abdominal discomfort, enlargement of the liver, or hemorrhage.
Diagnosis and pathology
Definitive diagnosis requires tissue examination, usually from a biopsy. Clinical appearance and imaging alone cannot reliably distinguish angiosarcoma from benign vascular lesions or other malignancies.
On histopathologic examination, relatively well-differentiated areas can show irregular, interconnected vascular channels lined by atypical endothelial cells. Poorly differentiated areas may consist largely of solid sheets of malignant cells, sometimes with an epithelioid appearance, and may show little obvious vessel formation.
Immunohistochemistry helps establish endothelial differentiation. Commonly used markers include CD31 and ERG. CD34 and other vascular markers can provide additional support, but no single stain is interpreted independently of the microscopic appearance and clinical context. Molecular testing, including assessment of MYC amplification in selected circumstances, may assist classification.
The differential diagnosis includes benign vascular proliferations, atypical vascular lesions arising after radiation, other malignant vascular tumors, melanoma, and poorly differentiated carcinoma. Epithelioid angiosarcoma can express cytokeratins, creating a particular diagnostic pitfall.
Assessment of extent
Cancer staging evaluates local tumor extent and distant spread. The approach varies with the primary site. Magnetic resonance imaging can help define soft-tissue involvement, while computed tomography is commonly used to assess the chest and other regions. Additional imaging is selected according to the tumor location and clinical findings.
Angiosarcoma can spread through the bloodstream, commonly involving the lungs. Other possible sites of metastasis include the liver, bone, and brain. Regional lymph-node involvement can also occur. Multifocal skin lesions may represent extensive local disease rather than separate unrelated tumors.
Treatment
Management is individualized because angiosarcoma is rare and encompasses several distinct clinical settings.
For localized, resectable disease, surgery aims to remove the tumor with microscopically clear margins. Achieving clear margins can be difficult, particularly with diffuse scalp or facial disease. Radiation therapy is frequently incorporated into local treatment, depending on the site, previous treatment, and feasibility.
For unresectable or metastatic disease, chemotherapy is a major treatment approach. Drugs used include taxanes, especially paclitaxel, and anthracycline-based regimens. Systemic treatment may also be used before surgery in selected cases.
Some targeted therapies have activity in advanced disease. Immune checkpoint inhibitors have produced responses in subsets of patients, including some with cutaneous scalp or facial tumors, but benefit is not uniform. Evidence for these approaches remains more limited than for many common cancers, and access or regulatory status varies.
Palliative care can address pain, bleeding, functional impairment, and other effects of the disease alongside tumor-directed treatment.
Prognosis and evidence limitations
Angiosarcoma has a substantial risk of local recurrence and distant spread, including after apparently complete removal. Prognosis depends on factors such as metastatic disease at diagnosis, primary site, tumor size and extent, and whether effective local control is achievable.
Survival estimates vary considerably between studies because they combine different anatomical sites, stages, treatment periods, and patient populations. The rarity of angiosarcoma also limits large comparative trials. Much of the evidence comes from retrospective series, small prospective studies, and broader soft-tissue sarcoma research, making results from one subgroup difficult to apply to all others.